Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy plus chemotherapy with maintenance and deferred local treatment in advanced hypopharyngeal cancer
ChiCTR2500114942Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in hypopharyngeal cancer, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Proportion of patients without local treatment at 1 year and 1-year progression-free survival (PFS) rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
hypopharyngeal cancer
Beyond the preview
Go deeper on ChiCTR2500114942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114942.